May 8, 2026 · Gynecologic oncology · DOI: 10.1016/j.ygyno.2026.04.020

Expression of the antibody-drug conjugate targets TROP2, CLDN6, B7-H3, and DLL3 in mesonephric-like adenocarcinoma of the female genital tract

Listen to this summary

This study investigates the expression of potential therapeutic targets TROP2, CLDN6, B7-H3, and DLL3 in mesonephric-like adenocarcinoma (MLA) of the female genital tract, aiming to identify candidates for antibody-drug conjugate (ADC) therapies. The results reveal that B7-H3, TROP2, and CLDN6 are consistently expressed in MLA, suggesting their viability as therapeutic targets, while DLL3 shows minimal expression and is unlikely to be useful for treatment. These findings support the clinical exploration of ADCs in this aggressive cancer type.

Xiaoming Zhang, Jahanbanoo Shahryari, Leandra G Kingsley, W Glenn McCluggage, Brooke E Howitt

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play